Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab in Schizophrenia
NCT07680946Phase 2Recruiting
- Sponsor
- TG Therapeutics, Inc.
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of ublituximab in schizophrenia, sponsored by TG Therapeutics, Inc.. Started Jul 2026; status: recruiting.
02
Drugs
ublituximab
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07680946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07680946.